KIT and mastocytosis: The inhibition of growth by SPHK1-I and SPHK2-I of primary neoplastic MCs from patients and of D816V-KIT MCs in vivo support the conclusion that SPHK inhibitors are appropriate candidates to consider for clinical applications in the treatment of mastocytosis.